Tempest Therapeutics Inc (TPST)

Currency in USD
2.2800
-0.0100(-0.44%)
Closed·
2.2000-0.0800(-3.51%)
·
TPST is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.20002.2800
52 wk Range
2.120012.2300
Key Statistics
Prev. Close
2.29
Open
2.22
Day's Range
2.2-2.28
52 wk Range
2.12-12.23
Volume
24.37K
Average Volume (3m)
114.07K
1-Year Change
-78.3315%
Book Value / Share
1.43
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TPST Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.0000
Upside
+382.46%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Tempest Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Compare TPST to Peers and Sector

Metrics to compare
TPST
Peers
Sector
Relationship
P/E Ratio
−0.9x−5.2x−0.6x
PEG Ratio
−0.02−0.100.00
Price/Book
4.8x3.1x2.6x
Price / LTM Sales
-63.9x3.3x
Upside (Analyst Target)
382.5%50.6%44.8%
Fair Value Upside
Unlock−6.9%5.5%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 11.0000
(+382.46% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy11.00+382.46%-Upgrade22/01/2026
H.C. Wainwright
Hold---Downgrade10/04/2025
Scotiabank
Hold9.00+294.74%-Downgrade10/04/2025
H.C. Wainwright
Buy16.00+601.75%47.00Maintain28/03/2025
Scotiabank
Buy7.00+207.02%13.00Maintain28/03/2025

Earnings

Latest Release
Nov 05, 2025
EPS / Forecast
-0.79 / -0.2917
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

0.49
CCHH
-3.92%
3.6400
WTO
+1.39%
0.183
CXAI
-3.17%
0.693
GNLN
+5.16%
9.140
VCIG
-23.06%

FAQ

What Is the Tempest Therapeutics (TPST) Share Price Today?

The Tempest Therapeutics stock price today is 2.2800 USD.

What Stock Exchange Does Tempest Therapeutics (TPST) Trade On?

Tempest Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Tempest Therapeutics?

The stock symbol (also called a 'ticker') for Tempest Therapeutics is "TPST."

What Is the Current Tempest Therapeutics Market Cap?

As of today, Tempest Therapeutics market cap is 30.7400M USD.

What Is Tempest Therapeutics's (TPST) Earnings Per Share (TTM)?

The Tempest Therapeutics EPS is currently -9.7146 (Trailing Twelve Months).

Is TPST a Buy or Sell From a Technical Analyst Perspective?

Based on today's Tempest Therapeutics moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Tempest Therapeutics Stock Split?

Tempest Therapeutics has split 3 times. (See the TPST stock split history page for full effective split date and price information.)

How Many Employees Does Tempest Therapeutics Have?

Tempest Therapeutics has 24 employees.

What is the current trading status of Tempest Therapeutics (TPST)?

As of 28/02/2026, Tempest Therapeutics (TPST) is trading at a price of 2.2800 USD, with a previous close of 2.2900 USD. The stock has fluctuated within a day range of 2.2000 USD to 2.2800 USD, while its 52-week range spans from 2.1200 USD to 12.2300 USD.

What Is Tempest Therapeutics (TPST) Price Target According to Analysts?

The average 12-month price target for Tempest Therapeutics is 11.0000 USD, with a high estimate of 11 USD and a low estimate of 11 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +382.46% Upside potential.

What Is the TPST Premarket Price?

TPST's last pre-market stock price is 2.2960 USD. The pre-market share volume is 4,080.0000, and the stock has decreased by 0.0060, or 0.2600%.

What Is the TPST After Hours Price?

TPST's last after hours stock price is 2.2000 USD, the stock has decreased by -0.0800, or -3.5100%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.